| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Pharmaceutical Sciences, Washington State University, Pullman, Washington 99164-6510 [S. S. D.], and Mathematical and Statistical Computing Laboratory, Center for Information Technology [P. J. M., L. Y., V. V. P.] and Laboratory of Molecular Pharmacology, Center for Cancer Research [W. R., Q. Y., J. L., K. W. K., J. N. W., Y. P.], National Cancer Institute, NIH, Bethesda, Maryland 20892-4255
To uncover transcriptional stress responses related to p53, we used cDNA microarrays (National Cancer Institute Oncochips comprising 6500 different genes) to characterize the gene expression profiles of wild-type p53 HCT-116 cells and an isogenic p53 knockout counterpart after treatment with topotecan, a specific topoisomerase I inhibitor. The use of the p53 knockout cells had the advantage over p53-overexpressing systems in that p53 activation is mediated physiologically. RNA was extracted after low (0.1 µM)- and high (1 µM)-dose topotecan at multiple time points within the first 6 h of treatment. To facilitate simultaneous study of the p53 status and pharmacological effects on gene expression, we developed a novel "cross-referenced network" experimental design and used multiple linear least squares fitting to optimize estimates of relative transcript levels in the network of experimental conditions. Approximately 10% of the transcripts were up- or down-regulated in response to topotecan in the p53+/+ cells, whereas only 1% of the transcripts changed in the p53-/- cells, indicating that p53 has a broad effect on the transcriptional response to this stress. Individual transcripts and their relationships were analyzed using clustered image maps and by a novel two-dimensional analysis/visualization, gene expression map, in which each gene expression level is represented as a function of both the genotypic/phenotypic difference (i.e., p53 status) and the treatment effect (i.e., of topotecan dose and time of exposure). Overall, drug-induced p53 activation was associated with a coherent genetic program leading to cell cycle arrest and apoptosis. We identified novel p53-induced and DNA damage-induced genes (the proapoptotic SIVA gene and a set of transforming growth factor ß-related genes). Genes induced independently of p53 included the antiapoptotic cFLIP gene and known stress genes related to the mitogen-activated protein kinase pathway and the Fos/Jun pathway. Genes that were negatively regulated by p53 included members of the antiapoptotic protein chaperone heat shock protein 70 family. Finally, among the p53-dependent genes whose expression was independent of drug treatment was S100A4, a small Ca2+-binding protein that has recently been implicated in p53 binding and regulation. The new experimental design and gene expression map analysis introduced here are applicable to a wide range of studies that encompass both treatment effects and genotypic or phenotypic differences.
This article has been cited by other articles:
|
|
 |
|
  D. L. Cottle, M. J. McGrath, B. R. Wilding, B. S. Cowling, J. M. Kane, C. E. D'Arcy, M. Holdsworth, I. Hatzinisiriou, M. Prescott, S. Brown, et al. SLIMMER (FHL1B/KyoT3) Interacts with the Proapoptotic Protein Siva-1 (CD27BP) and Delays Skeletal Myoblast Apoptosis J. Biol. Chem., September 25, 2009; 284(39): 26964 - 26977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Miller Jenkins, S. J. Mazur, M. Rossi, O. Gaidarenko, Y. Xu, and E. Appella Quantitative Proteomics Analysis of the Effects of Ionizing Radiation in Wild Type and p53K317R Knock-in Mouse Thymocytes Mol. Cell. Proteomics, April 1, 2008; 7(4): 716 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Stephens, H. Han, G. Hostetter, M. J. Demeure, and D. D. Von Hoff Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells Mol. Cancer Ther., January 1, 2008; 7(1): 202 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-T. Lin, Y.-J. Lai, N. Makarova, G. Tigyi, and W.-C. Lin The Lysophosphatidic Acid 2 Receptor Mediates Down-regulation of Siva-1 to Promote Cell Survival J. Biol. Chem., December 28, 2007; 282(52): 37759 - 37769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Orre, M. Pernemalm, J. Lengqvist, R. Lewensohn, and J. Lehtio Up-regulation, Modification, and Translocation of S100A6 Induced by Exposure to Ionizing Radiation Revealed by Proteomics Profiling Mol. Cell. Proteomics, December 1, 2007; 6(12): 2122 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-H. Miao, A. Player, U. Shankavaram, Y.-H. Wang, D. B. Zimonjic, P. L. Lorenzi, Z.-Y. Liao, H. Liu, T. Shimura, H.-L. Zhang, et al. Nonclassic Functions of Human Topoisomerase I: Genome-Wide and Pharmacologic Analyses Cancer Res., September 15, 2007; 67(18): 8752 - 8761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Fanton, M. W. Rowe, E. J. Moler, M. Ison-Dugenny, S. K. De Long, K. Rendahl, Y. Shao, T. Slabiak, T. G. Gesner, and M. L. MacKichan Development of a Screening Assay for Surrogate Markers of Chk1 Inhibitor-Induced Cell Cycle Release J Biomol Screen, October 1, 2006; 11(7): 792 - 806. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Malavazi, M. Savoldi, S. M. Z. Di Mauro, C. F. M. Menck, S. D. Harris, M. H. d. S. Goldman, and G. H. Goldman Transcriptome Analysis of Aspergillus nidulans Exposed to Camptothecin-Induced DNA Damage. Eukaryot. Cell, October 1, 2006; 5(10): 1688 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Stephens, H. Han, V. Gokhale, and D. D. Von Hoff PRL phosphatases as potential molecular targets in cancer Mol. Cancer Ther., November 1, 2005; 4(11): 1653 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Kovanen, L. Young, A. Al-Shami, V. Rovella, C. A. Pise-Masison, M. F. Radonovich, J. Powell, J. Fu, J. N. Brady, P. J. Munson, et al. Global analysis of IL-2 target genes: identification of chromosomal clusters of expressed genes Int. Immunol., August 1, 2005; 17(8): 1009 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mialon, M. Sankinen, H. Soderstrom, T. T. Junttila, T. Holmstrom, R. Koivusalo, A. C. Papageorgiou, R. S. Johnson, S. Hietanen, K. Elenius, et al. DNA Topoisomerase I Is a Cofactor for c-Jun in the Regulation of Epidermal Growth Factor Receptor Expression and Cancer Cell Proliferation Mol. Cell. Biol., June 15, 2005; 25(12): 5040 - 5051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Chu, J. Barkinge, S. Hawkins, R. Gudi, R. Salgia, and P. V.S. Kanteti Expression of Siva-1 Protein or Its Putative Amphipathic Helical Region Enhances Cisplatin-Induced Apoptosis in Breast Cancer Cells: Effect of Elevated Levels of BCL-2 Cancer Res., June 15, 2005; 65(12): 5301 - 5309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Torkin, J.-F. Lavoie, D. R. Kaplan, and H. Yeger Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma Mol. Cancer Ther., January 1, 2005; 4(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Giuliano, Y.-T. Chen, and D. L. Taylor High-Content Screening with siRNA Optimizes a Cell Biological Approach to Drug Discovery: Defining the Role of P53 Activation in the Cellular Response to Anticancer Drugs J Biomol Screen, October 1, 2004; 9(7): 557 - 568. [Abstract] [PDF]
|
|
|
|
|
|
A. Fortin, J. G. MacLaurin, N. Arbour, S. P. Cregan, N. Kushwaha, S. M. Callaghan, D. S. Park, P. R. Albert, and R. S. Slack The Proapoptotic Gene SIVA Is a Direct Transcriptional Target for the Tumor Suppressors p53 and E2F1 J. Biol. Chem., July 2, 2004; 279(27): 28706 - 28714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Lu, W. E. Burgan, M. A. Cerra, E. Y. Chuang, M.-H. Tsai, P. J. Tofilon, and K. Camphausen Transcriptional signature of flavopiridol-induced tumor cell death Mol. Cancer Ther., July 1, 2004; 3(7): 861 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rapisarda, B. Uranchimeg, O. Sordet, Y. Pommier, R. H. Shoemaker, and G. Melillo Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1: Mechanism and Therapeutic Implications Cancer Res., February 15, 2004; 64(4): 1475 - 1482. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
